A new study has suggested that lung cancer patients who received a drug designed to target a genetic dysfunction lived longer with fewer side effects than those who received traditional chemotherapy.
Researchers found that patients with an abnormal ALK gene who received Pfizer's targeted drug crizotinib remained cancer-free for nearly five months longer.
"This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics ...
A new study has suggested that lung cancer patients who received a drug designed to target a genetic dysfunction lived longer with fewer side effects than those who received traditional chemotherapy.
Researchers found that patients with an abnormal ALK gene who received Pfizer's targeted drug crizotinib remained cancer-free for nearly five months longer.
"This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics ...